** Shares of cancer therapy maker Novocure 
NVCR up 1.4% at $12.32 premarket
** Company says Japan’s health ministry has approved NVCR’s Optune Lua for patients with advanced or recurrent non-small cell lung cancer who have not responded to platinum-based chemotherapy
** The treatment uses Tumor Treating Fields, or electric fields, through a portable device, Optune Lua, placed on the skin near the tumor that targets cancer cells while sparing most nearby healthy cells
** The device was approved by the U.S. FDA in October 2024
** As of last close, stock down 59.2% YTD